GlassScriptPhysician profile
Katherine Herold
NPI 1568506749
$10,179.85
in general payments reported to CMS, 2019-2025
50 companies · $2,369 in 2025
The $2,369 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,613 · 2023: $3,169 · 2024: $3,029 · 2025: $2,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,558 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,558.22 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,616.96 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $951.19 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $866.10 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $759.63 | 2022-2025 | Hetlioz, Fanapt |
| Otsuka America Pharmaceutical, INC. | $520.08 | 2022-2025 | Rexulti, Abilify Maintena |
| Novo Nordisk INC | $514.54 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $475.41 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $393.44 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $341.53 | 2022-2025 | |
| Astellas Pharma US INC | $296.40 | 2023-2025 | Veozah, Myrbetriq |
| Amgen INC. | $237.26 | 2022-2025 | Repatha, Otezla, Repatha |
| Esperion Therapeutics, INC. | $230.93 | 2022-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $215.40 | 2023-2024 | Spravato, Xarelto |
| Lilly USA, LLC | $210.35 | 2022-2025 | Mounjaro, Trulicity, Jardiance |
| Exact Sciences Corporation | $209.49 | 2023-2025 | Cologuard Collection Kit |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Herold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.